Investment Management Associates Inc. ADV Makes New $5.20 Million Investment in Humana Inc. $HUM

Investment Management Associates Inc. ADV purchased a new position in shares of Humana Inc. (NYSE:HUM) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 19,966 shares of the insurance provider’s stock, valued at approximately $5,195,000. Humana accounts for approximately 1.5% of Investment Management Associates Inc. ADV’s portfolio, making the stock its 18th biggest holding.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Elevation Point Wealth Partners LLC purchased a new stake in Humana during the second quarter worth about $32,000. Mather Group LLC. bought a new position in shares of Humana during the 3rd quarter valued at approximately $34,000. AlphaCore Capital LLC bought a new position in shares of Humana during the 2nd quarter valued at approximately $39,000. Private Wealth Management Group LLC increased its stake in shares of Humana by 47.5% during the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 48 shares during the last quarter. Finally, SJS Investment Consulting Inc. raised its holdings in shares of Humana by 19,300.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 194 shares of the insurance provider’s stock worth $50,000 after purchasing an additional 193 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

HUM has been the subject of several research reports. The Goldman Sachs Group reduced their price objective on Humana from $235.00 to $215.00 and set a “sell” rating for the company in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a research report on Thursday, January 22nd. Jefferies Financial Group decreased their price objective on Humana from $313.00 to $310.00 and set a “buy” rating for the company in a report on Monday, January 26th. Robert W. Baird lowered their price objective on Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a research note on Thursday, December 11th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $344.00 target price on shares of Humana in a research report on Tuesday, January 6th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, Humana currently has an average rating of “Hold” and an average price target of $293.21.

Humana Stock Performance

Shares of HUM opened at $181.10 on Wednesday. Humana Inc. has a 52-week low of $180.89 and a 52-week high of $315.35. The stock’s 50-day simple moving average is $249.25 and its 200 day simple moving average is $262.36. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. The stock has a market capitalization of $21.78 billion, a price-to-earnings ratio of 16.97, a price-to-earnings-growth ratio of 1.57 and a beta of 0.44.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.